What TG Therapeutics, Inc.’s (NASDAQ:TGTX) 26% Share Price Gain Is Not Telling You
TG Therapeutics, Inc. (NASDAQ:TGTX) shareholders would be excited to see that the share price has had a great month, posting a 26% gain and recovering from prior weakness. The last 30 days bring the annual gain to a very sharp 57%.
Although its price has surged higher, it’s still not a stretch to say that TG Therapeutics’ price-to-sales (or “P/S”) ratio of 11.8x right now seems quite “middle-of-the-road” compared to the Biotechs industry in the United States, where the median P/S ratio is around 10x. While this might not raise any eyebrows, if the P/S ratio is not justified investors could be missing out on a potential opportunity or ignoring looming disappointment.
